Markets
MRK

Immune Design Starts Mid-Stage Soft Tissue Sarcoma Trial

A generic image of a pen, a calculator and sheets
Credit: Shutterstock photo

Immune Design Corp.IMDZ announced that it has commenced a randomized phase II study on its "prime boost" immunotherapy candidate, CMB305, in combination with Genentech's (a subgroup of Roche Holding AG RHHBY ) cancer immunotherapy candidate, atezolizumab, for the treatment of patients with soft tissue sarcoma.

According to the National Cancer Institute, almost 12,000 people are expected to be diagnosed with soft tissue sarcoma in 2015 with about 4,870 people expected to die of the disease in 2015.

We note that G100 and LV305, Immune Design's other pipeline candidates, are being developed in collaboration with Merck & Co. Inc.'s MRK Keytruda in patients with non-Hodgkin lymphoma and melanoma, respectively. The company also completed enrollment for a phase I study on G100 in patients with Merkel cell carcinoma.

The company is planning to present pre-clinical data on G100 at the annual meeting of the American Society of Hematology in early December.

Meanwhile, late last month, Immune Design announced that one of its collaboration partners, MedImmune, started a phase II study on MEDI7510 for the prevention of respiratory syncytial virus (RSV). We note that MEDI7510 comprises MedImmune's RSV sF antigen plus GLA, a synthetic molecule licensed from Immune Design's GLAAS discovery platform.

MedImmune has an exclusive license to use the GLAAS platform to develop and commercialize vaccines for two different infectious disease indications including RSV.

Immune Design carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Corcept Therapeutics Incorporated CORT , carrying Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

CORCEPT THERAPT (CORT): Free Stock Analysis Report

IMMUNE DESIGN (IMDZ): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRK CORT RHHBY

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More